Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13591239 | 0.80 | MAPT (0.40) | CYP19A1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL25832069 | 0.80 | MAPT (0.40) | MAPTALDH1A1C3AR1 | |
| SCHEMBL25832222 | 0.77 | KMT2A (0.31) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL25832194 | 0.74 | NPC1 (0.30) | ALDH1A1 | |
| SCHEMBL25832160 | 0.70 | CYP19A1 (0.55) | CYP19A1KMT2AMAOB | |
| SCHEMBL11953407 | 0.66 | ALOX15B (0.43) | CYP19A1MAPTALDH1A1TP53 | |
| SCHEMBL11926947 | 0.66 | ALOX15B (0.43) | CYP19A1MAPTALDH1A1TP53 | |
| SCHEMBL25832189 | 0.63 | ACAT2 (0.39) | MAPTALDH1A1MEN1KMT2AC3AR1 | |
| SCHEMBL12433393 | 0.63 | ALOX15B (0.43) | CYP19A1ALDH1A1MAOB | |
| SCHEMBL22068562 | 0.62 | CA2 (0.53) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | CYP19A1 1123/4885MAPT 551/4885ALDH1A1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.